Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada

This analysis compared the cost-effectiveness of once-daily regimens of mirabegron 50 mg and generic tolterodine ER 4 mg in a hypothetical cohort of previously treated patients with overactive bladder (OAB) in Canada